HomeCompareDVAX vs EPRT

DVAX vs EPRT: Dividend Comparison 2026

DVAX yields 12.90% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $16.6K in total portfolio value· pulled ahead in Year 8
10 years
DVAX
DVAX
● Live price
12.90%
Share price
$15.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$2,879.44
Full DVAX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — DVAX vs EPRT

📍 EPRT pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVAXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVAX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DVAX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVAX
Annual income on $10K today (after 15% tax)
$1,096.77/yr
After 10yr DRIP, annual income (after tax)
$2,447.52/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $8,467.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVAX + EPRT for your $10,000?

DVAX: 50%EPRT: 50%
100% EPRT50/50100% DVAX
Portfolio after 10yr
$55.1K
Annual income
$7,860.08/yr
Blended yield
14.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

DVAX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$27.00
+74.2% upside vs current
Range: $20.00 — $32.00
Altman Z
2.4
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVAX buys
0
EPRT buys
0
No recent congressional trades found for DVAX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVAXEPRT
Forward yield12.90%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$46.8K$63.4K
Annual income after 10y$2,879.44$12,840.73
Total dividends collected$20.6K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$27.00$35.50

Year-by-year: DVAX vs EPRT ($10,000, DRIP)

YearDVAX PortfolioDVAX Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,990$1,290.32$11,205$505.18+$785.00DVAX
2$14,276$1,445.92$12,672$682.46+$1.6KDVAX
3$16,884$1,608.88$14,490$930.48+$2.4KDVAX
4$19,844$1,778.34$16,786$1,282.69+$3.1KDVAX
5$23,186$1,953.40$19,753$1,791.56+$3.4KDVAX
6$26,943$2,133.11$23,677$2,541.64+$3.3KDVAX
7$31,145$2,316.51$29,008$3,672.99+$2.1KDVAX
8← crossover$35,828$2,502.66$36,463$5,425.08$635.00EPRT
9$41,026$2,690.60$47,238$8,221.57$6.2KEPRT
10$46,778$2,879.44$63,385$12,840.73$16.6KEPRT

DVAX vs EPRT: Complete Analysis 2026

DVAXStock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Full DVAX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this DVAX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVAX vs SCHDDVAX vs JEPIDVAX vs ODVAX vs KODVAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.